Physician profile
Charles Putney Allison
NPI 1376541060
$6,534.12
in general payments reported to CMS, 2019-2025
33 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $627 · 2021: $13.87 · 2022: $108 · 2023: $1,214 · 2024: $1,888 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,708 · Education: $33.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.63 |
| Education | $33.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $819.95 | 2020-2025 | Cabenuva, Rukobia, Apretude |
| Merck Sharp & Dohme LLC | $684.22 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Lilly USA, LLC | $630.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $573.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $557.31 | 2019-2025 | |
| Gilead Sciences, INC. | $456.16 | 2019-2025 | Biktarvy |
| Glaxosmithkline, LLC. | $342.54 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.45 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $280.42 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $251.73 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $226.43 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $162.48 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.74 | 2019-2023 | Eliquis, Camzyos |
| Theratechnologies INC. | $152.41 | 2023-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $147.66 | 2019-2023 | Symtuza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $86.73 | 2019-2020 | |
| Amgen INC. | $70.52 | 2023-2025 | Evenity, Prolia, Prolia |
| Regeneron Healthcare Solutions, INC. | $69.06 | 2019-2024 | Evkeeza |
| Xeris Pharmaceuticals, INC. | $66.47 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $64.99 | 2019-2025 | |
| Circassia INC. | $53.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $44.91 | 2020 | |
| Dexcom, INC. | $43.37 | 2024 | Dexcom G6 Transmitter |
| Agios Pharmaceuticals, INC. | $37.59 | 2025 | Pyrukynd |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.53 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.12 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $33.70 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $32.54 | 2020 | |
| Sumitomo Pharma America, INC. | $29.27 | 2025 | Gemtesa |
| Bausch Health US, LLC | $23.20 | 2023 | Aplenzin |
| Napo Pharmaceuticals INC | $21.52 | 2023 | Mytesi |
| Abbott Laboratories | $15.99 | 2020 | |
| Radius Health, INC. | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.